Innovation & Pipeline Topic Center

Videos

Designing Early-Phase Radioligand Therapy Trials: What Makes Them Different?

02/12/2026

Aman Chauhan, MD

Aman Chauhan, MD, discusses how early-phase radioligand therapy trials differ from conventional phase 1 oncology studies by incorporating dosimetry, imaging-based biomarkers, cumulative radiation safety considerations, and additional...

Aman Chauhan, MD, discusses how...

02/12/2026

Radiopharmaceutical Education Institute

Praful Ravi, MB, BChir, MRCP, Dana-Farber Cancer Institute

Videos

PSMA Radioligand Therapy in Hormone-Sensitive Prostate Cancer: Lessons from the PSMAddition Trial

02/12/2026

Praful Ravi, MB, BChir, MRCP

Praful Ravi, MB, BChir, MRCP, discusses the potential role of PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer, highlighting radiographic PFS benefits from the PSMAddition trial while emphasizing the need to balance...

Praful Ravi, MB, BChir, MRCP,...

02/12/2026

Radiopharmaceutical Education Institute

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

Innovation & Pipeline Topic Center

Advancing Oncology Through Radiopharmaceutical Innovation

HMP Global Products

Events